Metropolitan Life Insurance Company (MetLife)’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-6,447
| Closed | -$152K | – | 2360 |
|
|
2023
Q4 | $152K | Buy |
6,447
+779
| +14% | +$13.9K | 0.01% | 870 |
|
|
2023
Q3 | $84.5K | Buy |
5,668
+300
| +6% | +$3.98K | ﹤0.01% | 1102 |
|
|
2023
Q2 | $58.8K | Buy |
+5,368
| New | +$50K | ﹤0.01% | 1326 |
|
|
2022
Q2 | – | Sell |
-6,132
| Closed | -$19.1K | – | 2453 |
|
|
2022
Q1 | $19.1K | Buy |
+6,132
| New | +$19.3K | ﹤0.01% | 2121 |
|
|
2021
Q4 | – | Sell |
-20,041
| Closed | -$73.2K | – | 2844 |
|
|
2021
Q3 | $73.2K | Buy |
+20,041
| New | +$79K | ﹤0.01% | 2685 |
|
|
2021
Q2 | – | Sell |
-22,403
| Closed | -$102K | – | 2933 |
|
|
2021
Q1 | $102K | Buy |
22,403
+11,789
| +111% | +$63.4K | ﹤0.01% | 2421 |
|
|
2020
Q4 | $60.9K | Sell |
10,614
-4,257
| -29% | -$32.2K | ﹤0.01% | 2456 |
|
|
2020
Q3 | $108K | Sell |
14,871
-9,202
| -38% | -$49.2K | ﹤0.01% | 2170 |
|
|
2020
Q2 | $84K | Buy |
+24,073
| New | +$69.5K | ﹤0.01% | 2358 |
|
|
2019
Q4 | – | Sell |
-20,599
| Closed | -$105K | – | 2573 |
|
|
2019
Q3 | $105K | Buy |
20,599
+699
| +4% | +$4.23K | ﹤0.01% | 2275 |
|
|
2019
Q2 | $142K | Hold |
19,900
| – | – | ﹤0.01% | 2118 |
|
|
2019
Q1 | $264K | Hold |
19,900
| – | – | ﹤0.01% | 1710 |
|
|
2018
Q4 | $157K | Hold |
19,900
| – | – | ﹤0.01% | 1968 |
|
|
2018
Q3 | $220K | Hold |
19,900
| – | – | ﹤0.01% | 1945 |
|
|
2018
Q2 | $267K | Buy |
+19,900
| New | +$249K | ﹤0.01% | 1748 |
|
Other funds holding CBAY
Metropolitan Life Insurance Company (MetLife)'s CBAY Position: Q1 2024 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 6,447 shares — an estimated $152K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in CBAY in Q2 2018 and held it in 15 quarters. The position peaked at $267K in Q2 2018. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 6,447 Cymabay Therapeutics shares in Q1 2024, an estimated $152K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 15 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Cymabay Therapeutics position peaked at $267K in Q2 2018.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2024, filed 14 May 2024.